Study on Belzutifan for Treating Advanced Tumors Related to Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Gastrointestinal Stromal Tumor, or Solid Tumors with HIF-2α Genetic Changes

Inclusion Criteria

• Diagnosed with specific types of advanced tumors, such as pheochromocytoma/paraganglioma, pancreatic neuroendocrine tumors, or Von Hippel-Lindau disease-associated tumors.
• Tumors must be advanced or have spread and cannot be treated with surgery or other curative treatments.
• For certain tumors, patients must have tried other treatments without success.
• Must have measurable disease as determined by scans.
• Must be 18 years or older.
• Must have controlled blood pressure if applicable.
• Must not have tumors that require immediate surgery.
• Must agree to use effective contraception if of childbearing potential.
• Must provide a tumor sample for analysis.
• Must have a good performance status and adequate organ function.
• Must have a life expectancy of at least 3 months.

Exclusion Criteria

• Unable to swallow pills or have issues with drug absorption.
• Have another type of cancer unless treated and cancer-free for 2 years.
• Have known brain metastases or certain heart conditions.
• Have uncontrolled high blood pressure.
• Have low oxygen levels or need oxygen therapy.
• Have a psychiatric or substance abuse disorder affecting study participation.
• Have had major surgery or certain treatments recently.
• Have received certain cancer treatments or therapies recently.
• Have a known allergy to the study drug.
• Have not recovered from side effects of previous treatments.
• Have active infections or certain viral infections like HIV or hepatitis.
• Have had an organ transplant.
• Have uncontrolled symptoms from certain tumors.